IMPACTUL COVID-19 ASUPRA BPOC: COMPLICAȚIILE PE TERMEN SCURT ȘI CONSECINȚE PE TERMEN LUNG

Autori

  • Diana CONDRAȚCHI IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”
  • Serghei PISARENСO IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”
  • Constantin MARTINIUC IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”
  • Larisa PROCOPIȘIN IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”
  • Corina ROTARU-LUNGU IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”

DOI:

https://doi.org/10.52692/1857-0011.2024.2-79.47

Cuvinte cheie:

COVID-19, BPOC, complicații, patofiziologie, reabilitare respiratorie, inflamație, furtună citokinică, disfuncție endotelială, consecințe pe termen lung, sindrom post-COVID

Rezumat

Pandemia de COVID-19 a afectat grav pacienții cu bronhopneumopatie cronică obstructivă (BPOC), accentuând vulnerabilitatea acestora pentru complicații severe. Expresia crescută a receptorilor ACE2 și inflamația cronică la pacienții cu BPOC contribuie la agravarea infecției COVID-19, crescând riscul de complicații precum sindromul de detresă respiratorie acută, hipoxie și tromboze. Pe termen lung, la pacienții cu BPOC, COVID-19 este asociat cu fibroză pulmonară și sindrom post-COVID manifestat prin oboseală cronică și activitate fizică redusă. Lucrarea își propune să analizeze mecanismele patofiziologice, consecințele COVID-19 pe termen scurt și lung pentru pacienții cu BPOC și să ofere recomandări clinice pentru a le îmbunătăți calitatea vieții.

Biografii autori

Diana CONDRAȚCHI, IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”

cercetător științific

Serghei PISARENСO , IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”

dr. hab. în șt. med., conf. univer.

Constantin MARTINIUC, IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”

dr. hab. în șt. med., conf. cercet.

Larisa PROCOPIȘIN , IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”

dr. în șt. med., conf. cercet.

Corina ROTARU-LUNGU , IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”

cercet. științific.

Referințe

Alqahtani, J. S., et al. COVID-19 and Respiratory Disease: A Systematic Review of COPD and Smoking as Risk Factors. Chest, vol. 158, no. 5, 2020, pp. 1511- 1530.

Alqahtani, J. S., et al. Prevalence, Severity, and Mortality Associated with COPD and Smoking in Patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLOS ONE, vol. 15, no. 5, 2020.

Alter, P., et al. Impact of the COVID-19 Pandemic on the Behaviour and Health Status of Patients with COPD: Results from the German COPD Cohort COSYCONET. ERJ Open Research, vol. 7, no. 1, 2021, https://doi.org/10.1183/23120541.00542-2020.

Benitez, I. D., et al. Impact of COVID-19 on COPD Exacerbations and Clinical Course. Discover Public Health, vol. 1, 2024.

Gheblawi, M., Wang, K., Viveiros, A., et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circulation research, 126(10), 2020, 1456–1474.

Global Initiative for Chronic Obstructive Lung Disease. GOLD Report 2024: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2024.

Hatipoğlu, U., et al. Inhaled Corticosteroids Do Not Adversely Impact Outcomes in COVID-19 Positive Patients with COPD: An Analysis of Cleveland Clinic’s COVID-19 Registry. PLOS ONE, vol. 16, no. 6, 2021.

Hatipoğlu, U., et al. Inhaled Corticosteroids Do Not Adversely Impact Outcomes in COVID-19 Positive Patients with COPD: An Analysis of Cleveland Clinic’s COVID-19 Registry. PLOS ONE, vol. 16, no. 6, 2021.

Hoffmann, M., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, vol. 181, no. 2, 2020, pp. 271-280.

Hoffmann, M., et al. The Interaction of SARS- CoV-2 with ACE2 Receptors: Pathophysiological Implications. European Respiratory Journal, vol. 55, no. 2, 2020, pp. 123-131.

Iglesias, C., et al. Reduction in Hospitalised COPD Exacerbations During COVID-19: A Systematic Review and Meta-Analysis. Respiratory Medicine, vol. 175, 2020.

Kim, Y. J., et al. Impact of COPD on COVID-19 Prognosis: A Nationwide Population-Based Study in South Korea. Journal of Korean Medical Science, vol. 35, no. 37, 2020.

Libby, P., Lüscher, T. COVID-19 is, in the end, an endothelial disease. European heart journal, 41(32), 2020, 3038–3044.

Singh, D., et al. Characteristics and Prognosis of COVID-19 in Patients with COPD. The Lancet Respiratory Medicine, vol. 9, no. 4, 2021, pp. 330-338.

Siviero, P., et al. The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic. International Journal of COPD, vol. 15, 2020, pp. 2247-2254.

Sosnowski, K., et al. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Journal of Respiratory Medicine, vol. 118, 2021, pp. 132-139.

Varga, Z., Flammer, A.J., Steiger, P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet (London, England), 395(10234), 2020, 1417–1418.

World Health Organization. Coronavirus Disease (COVID-19): Post COVID-19 Condition. World Health Organization, 2021, www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.

Yohannes, A. M. COPD Patients in a COVID-19 Society: Depression and Anxiety. Expert Review of Respiratory Medicine, vol. 15, no. 8, 2021, pp. 993- 1000.

Zhao, Q., et al. The Impact of COPD and Smoking History on the Severity of COVID‐19: A Systemic Review and Meta‐Analysis. Journal of Medical Virology, 2020.

Descărcări

Publicat

2025-04-18

Număr

Secțiune

Articol de cercetare

##category.category##